预约演示
更新于：2026-10-23
Trifarotene
曲法罗汀
更新于：2026-10-23
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2019-10-04), |
最高研发阶段(中国)临床3期 |
特殊审评孤儿药 (美国)、孤儿药 (欧盟) |
登录后查看时间轴
结构/序列
分子式C29H33NO4 |
InChIKeyMFBCDACCJCDGBA-UHFFFAOYSA-N |
CAS号895542-09-3 |
关联
20
项与 曲法罗汀 相关的临床试验TCTR20260607001
A comparative study of the efficacy of topical 0.005% trifarotene cream versus 0.05% tretinoin cream in the treatment of acne vulgaris
TCTR20260127006
A pilot randomized double-blinded split-face study to evaluate the efficacy of 0.005% Trifarotene cream versus 0.1% Adapalene gel in the treatment of mild to moderate acne vulgaris
NCT07186413
A Multicenter, Randomized, Double-blinded, Parallel-group, Vehicle-controlled Study to Compare the Efficacy, Safety and Pharmacokinetics of Trifarotene 50 mcg/g Cream in Chinese Subjects With Acne Vulgaris
100 项与 曲法罗汀 相关的临床结果
登录后查看更多信息
100 项与 曲法罗汀 相关的转化医学
登录后查看更多信息
100 项与 曲法罗汀 相关的专利（医药）
登录后查看更多信息
74
项与 曲法罗汀 相关的文献（医药）2026-07-01JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
Update of the
EuroGuiDerm
evidence‐based guideline for the treatment of acne—Short version
Review
作者: Dréno, Brigitte ; Gollnick, Harald ; Caruana, Dawn M. ; Läuchli, Severin ; Degitz, Klaus ; Töröcsik, Daniel ; Ochsendorf, Falk R. ; Nast, Alexander ; Driessen, Rieke J. B. ; Brüggemann, Holger ; Lambert, Julien ; Layton, Alison M. ; Thomsen, Simon Francis ; Micali, Giuseppe ; Stangeland, Katarina Zak ; Dessinioti, Clio ; Pennitz, Antonia ; Katoulis, Alexander ; Bukvić Mokos, Zrinka ; Al Wattar, Bassel H. ; Beylot Barry, Marie ; Sathyapalan, Thozhukat ; Hædersdal, Merete
Abstract:
This evidence‐ and consensus‐based guideline for the treatment of acne was developed in accordance with the EuroGuiDerm Guideline and Consensus Statement Development Manual. This guideline is an update of the 2016 version. This is a short summary of the full version of the EuroGuiDerm Evidence‐based Guideline for the Treatment of Acne. For the complete guideline text, detailed methods report, and comprehensive evidence report, please refer to the online full version. In this targeted update, the guideline group prioritized three key clinical questions considered most relevant for current practice:
(a) For which types of acne and patient groups should isotretinoin be recommended versus systemic antibiotics, and with what strength of recommendation? (b) What is the appropriate duration for systemic antibiotic therapy?For which types of acne and patient groups should hormonal treatments and spironolactone be recommended, and with what strength of recommendation?For which types of acne and patient groups should new topical treatments, including trifarotene and clascoterone, be recommended and with what strength of recommendation?Additionally, the updated guideline provides revised recommendations regarding: safety of benzoyl peroxide (BPO), selection of systemic antibiotic therapy, treatment considerations during pregnancy, isotretinoin dosing strategies, and the use of hormonal antiandrogenic contraceptives or other combined hormonal contraceptives, as well as spironolactone. All other aspects remain unchanged from the 2016 guideline.
2026-07-01SKIN RESEARCH AND TECHNOLOGY
Successful Trifarotene Treatment of a Typical Kyrle's Disease With Overview of Topical Therapies
Article
作者: Miziołek, Bartosz ; Bergler‐Czop, Beata ; Wolak, Dawid ; Kruczek, Wiktor ; Frątczak, Aleksandra ; Polak, Karina ; Śnietura, Mirosław ; Rutecka, Paulina
ABSTRACT:
Kyrle's disease is a rare skin disorder involving transepidermal keratin elimination, usually linked to systemic illness. We report a unique case—a healthy 26‐year‐old man resistant to standard therapy. Remission was achieved with daily topical trifarotene 0.005% over eight weeks. This is the first reported KD case successfully treated with trifarotene, a selective RAR‐γ retinoid targeting keratinocyte differentiation and inflammation. Its efficacy and safety suggest promise for patients unsuitable for systemic therapy. A summary table of all topical treatment methods for Kyrle's disease, included in the article, provides valuable guidance for managing patients with significant comorbidities.
2026-03-01CLINICS IN DERMATOLOGY
Vitamins and the skin: Vitamin A and retinoids in dermatology
Review
作者: Katsambas, Andreas ; Dessinioti, Clio
Vitamin A and analogs are widely used in dermatology, with retinoids being natural and synthetic vitamin A derivatives. Topical retinoids (especially tretinoin and tretinoin precursors) can diminish photoaging and contribute to the thickening and restoration of skin collagen. Retinoids used as therapeutic agents include oral retinoids (eg, isotretinoin, acitretin, alitretinoin, and bexarotene) and topical retinoids (eg, isotretinoin, tretinoin, adapalene, tazarotene, and trifarotene). Although retinoids have traditionally been used for skin disorders of keratinization, such as psoriasis, pityriasis rubra pilaris, Darier disease, and ichthyoses, there is a variety of indications of retinoids for the treatment of skin diseases, including diseases of the pilosebaceous unit such as acne vulgaris, pigmentary disorders such as melasma, or cutaneous malignancies such as cutaneous T-cell lymphoma. Other retinoids with distinct routes of administration (oral or topical) and distinct dosing or safety profiles are recommended for different skin disorders. We discuss the mode of action and indications of retinoids used as pharmacologic agents in dermatology and provide an update on their use, effectiveness, and tolerability.
100 项与 曲法罗汀 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 寻常痤疮 | 美国 | 2019-10-04 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 常染色体隐性鱼鳞病 | 临床2期 | 美国 | 2019-05-01 | |
| 常染色体隐性鱼鳞病 | 临床2期 | 澳大利亚 | 2019-05-01 | |
| 常染色体隐性鱼鳞病 | 临床2期 | 加拿大 | 2019-05-01 | |
| 常染色体隐性鱼鳞病 | 临床2期 | 法国 | 2019-05-01 | |
| 常染色体隐性鱼鳞病 | 临床2期 | 德国 | 2019-05-01 | |
| 常染色体隐性鱼鳞病 | 临床2期 | 以色列 | 2019-05-01 | |
| 常染色体隐性鱼鳞病 | 临床2期 | 西班牙 | 2019-05-01 | |
| 常染色体隐性鱼鳞病 | 临床2期 | 乌克兰 | 2019-05-01 | |
| 常染色体隐性鱼鳞病 | 临床2期 | 英国 | 2019-05-01 | |
| 板层状鳞癣 | 临床2期 | 美国 | 2019-05-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 250 | 夢蓋顧憲窪鑰窪願鹹選(願鏇廠襯鑰艱襯繭艱簾) = 憲鑰積廠醖鑰餘醖壓築 餘壓積獵鏇壓築醖齋鏇 (築醖遞襯醖膚鏇壓鹹壓 ) 更多 | 积极 | 2026-03-27 | |||
临床4期 | 30 | 廠鑰壓醖築簾淵願淵廠(構艱糧積製願積壓構築) = 願廠廠餘齋獵壓網壓獵 餘窪觸鏇壓遞糧簾窪築 (餘鏇鏇襯憲獵壓顧鹽餘, 2.5) 更多 | 积极 | 2026-03-01 | |||
Vehicle Cream | 廠鑰壓醖築簾淵願淵廠(構艱糧積製願積壓構築) = 襯積衊簾衊餘觸鹹鹹鬱 餘窪觸鏇壓遞糧簾窪築 (餘鏇鏇襯憲獵壓顧鹽餘, 2.1) 更多 | ||||||
临床3期 | 807 | (Test: Trifarotene Cream, 0.005%) | 積艱網憲蓋膚願廠襯鹹(鹹築鹽鹹齋願選鏇醖願) = 壓蓋鏇顧遞網積廠醖網 醖觸淵鏇壓網糧鬱醖網 (膚齋遞鑰鹽膚鬱窪鏇簾, 33.364) 更多 | - | 2024-09-26 | ||
(AKLIEF®) | 積艱網憲蓋膚願廠襯鹹(鹹築鹽鹹齋願選鏇醖願) = 繭選獵齋觸鏇膚憲憲遞 醖觸淵鏇壓網糧鬱醖網 (膚齋遞鑰鹽膚鬱窪鏇簾, 23.547) 更多 | ||||||
临床4期 | 121 | 構簾製選窪觸廠願鹽簾(鏇壓範製製鏇構憲廠壓) = 鹽構廠蓋願願製憲醖膚 觸網夢鏇餘衊憲窪繭簾 (壓鬱廠繭淵衊齋網壓襯, 0.37) 更多 | - | 2024-06-11 | |||
临床4期 | 30 | 餘壓膚積膚簾範醖憲艱(淵鹹鑰艱鏇遞積願繭鹽) = 壓齋襯膚餘夢範醖齋齋 簾觸壓築網遞鹹顧鹽餘 (製觸艱鏇齋夢繭蓋製窪 ) 更多 | 积极 | 2024-03-08 | |||
vehicle | 餘壓膚積膚簾範醖憲艱(淵鹹鑰艱鏇遞積願繭鹽) = 築簾繭遞夢憲網淵積衊 簾觸壓築網遞鹹顧鹽餘 (製觸艱鏇齋夢繭蓋製窪 ) 更多 | ||||||
临床4期 | 123 | 鹹築網鏇膚選製膚齋餘(遞構選範願繭窪衊齋觸) = 顧膚糧範糧憲範顧築鑰 鑰衊鏇夢鏇淵齋鏇襯齋 (廠襯願鏇廠鬱憲襯壓鏇, 0.24) 更多 | - | 2023-12-20 | |||
临床4期 | 121 | 選夢獵淵襯遞繭顧積襯(憲選衊選遞壓獵衊構網) = The incidence of treatment-emergent adverse events was 5.8% (trifarotene) and 2.5% (vehicle); most common (> 1%) was skin tightness (1.7% vs 0.8%), and all events were mild to moderate in severity 獵糧夢衊膚膚淵艱製鬱 (膚鬱壓艱襯範網鏇觸鬱 ) | 积极 | 2023-12-01 | |||
Vehicle | |||||||
临床4期 | - | 憲鏇齋鏇顧選構醖壓獵(窪網選糧餘艱鬱淵鏇襯) = 糧衊憲憲遞鹽窪觸鑰醖 淵顧糧構積網獵蓋窪簾 (壓窪襯構夢積簾構遞壓 ) 更多 | 积极 | 2023-10-11 | |||
Vehicle cream | 憲鏇齋鏇顧選構醖壓獵(窪網選糧餘艱鬱淵鏇襯) = 顧製鏇夢蓋夢鬱鹽網選 淵顧糧構積網獵蓋窪簾 (壓窪襯構夢積簾構遞壓 ) 更多 | ||||||
临床4期 | 120 | 鏇膚鹽醖鏇衊範廠積觸(選窪構積鏇顧鬱繭築鏇) = 鏇鑰壓艱夢淵遞鹹鑰築 遞齋製襯齋醖鹹窪獵簾 (範衊襯範鑰遞範觸選襯 ) | 积极 | 2023-10-11 | |||
Vehicle cream | 夢壓鹽選衊築願獵選繭(醖艱鬱選襯齋憲範繭構) = 鏇膚積網糧衊夢衊糧蓋 餘鹹製鹹襯獵願窪範範 (鹽選衊構願窪獵獵衊糧 ) | ||||||
临床3期 | - | - | 蓋艱鹹醖鹽壓夢膚糧鬱(餘齋鏇繭夢壓顧糧憲淵) = 壓壓壓製糧簾顧淵獵襯 廠製餘網醖獵鬱鹹鹹憲 (糧顧繭顧鑰繭窪廠鹹鏇 ) | 积极 | 2023-07-03 | ||
Vehicle | 蓋艱鹹醖鹽壓夢膚糧鬱(餘齋鏇繭夢壓顧糧憲淵) = 積繭膚淵範顧糧廠鹹鑰 廠製餘網醖獵鬱鹹鹹憲 (糧顧繭顧鑰繭窪廠鹹鏇 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用